(Q37981986)

26 August 2017

title

FGF receptor inhibitors: role in cancer therapy (English)

1 reference

26 August 2017

1

1 reference

26 August 2017

Jesus Corral

2

1 reference

26 August 2017

L Rhoda Molife

series ordinal

3

1 reference

26 August 2017

Johann S de Bono

series ordinal

4

1 reference

26 August 2017

publication date

1 April 2012

1 reference

26 August 2017

published in

Current Oncology Reports

1 reference

26 August 2017

volume

14

1 reference

26 August 2017

issue

2

1 reference

26 August 2017

page(s)

111-119

1 reference

https://scigraph.springernature.com/pub.10.1007/s11912-012-0225-0

26 August 2017

exact match

0 references

cites work

The FGF family: biology, pathophysiology and therapy

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

Fibroblast growth factor signalling: from development to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

Structural and Functional Diversity in the FGf Receptor Multigene Family

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

Cellular signaling by fibroblast growth factor receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

Perturbations of the AKT signaling pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

Fibroblast growth factor receptor 3 associates with and tyrosine phosphorylates p90 RSK2, leading to RSK2 activation that mediates hematopoietic transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

Cbl: many adaptations to regulate protein tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

Angiogenic growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

Inhibition of telomerase activity by HDV ribozyme in cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

The role of fibroblast growth factors and their receptors in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

Role of fibroblast growth factor 8 in growth and progression of hormonal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

Gene amplification profiling of esophageal squamous cell carcinomas by DNA array CGH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

High-resolution single nucleotide polymorphism array analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

Fibroblast growth factor receptor 3-IIIc mediates colorectal cancer growth and migration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

Clinical and biological characteristics of cervical neoplasias with FGFR3 mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

Drug-sensitive FGFR2 mutations in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

Multikinase inhibitors: a new option for the treatment of thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

Monoclonal antibody antagonists of hypothalamic FGFR1 cause potent but reversible hypophagia and weight loss in rodents and monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

Envisioning the future of early anticancer drug development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0225-0

Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models

21 January 2018

1 reference

12 December 2020

Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups

1 reference

12 December 2020

Fusion of ETV6 to fibroblast growth factor receptor 3 in peripheral T-cell lymphoma with a t(4;12)(p16;p13) chromosomal translocation.

1 reference

12 December 2020

Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance

1 reference

12 December 2020

Involvement of the FGF18 gene in colorectal carcinogenesis, as a novel downstream target of the beta-catenin/T-cell factor complex

1 reference

12 December 2020

Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis

1 reference

12 December 2020

Fibroblast growth factor receptor (FGFR) 3. Alternative splicing in immunoglobulin-like domain III creates a receptor highly specific for acidic FGF/FGF-1.

1 reference

12 December 2020

Regulation of the expression balance of angiopoietin-1 and angiopoietin-2 by Shh and FGF-2

1 reference

12 December 2020

Common variants on chromosome 5p12 confer susceptibility to estrogen receptor–positive breast cancer

1 reference

12 December 2020

Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas

1 reference

12 December 2020

An open-label dose-escalation study of BIBF 1120 in patients with relapsed or refractory multiple myeloma

1 reference

12 December 2020

Structural and functional diversity in the FGF receptor multigene family

1 reference

12 December 2020

Brivanib, a novel dual VEGF-R2/bFGF-R inhibitor.

1 reference

12 December 2020

FGF signaling in skeletal development.

1 reference

12 December 2020

Focal amplifications are associated with high grade and recurrences in stage Ta bladder carcinoma.

1 reference

12 December 2020

High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer

1 reference

12 December 2020

FrequentFGFR3mutations in urothelial papilloma

1 reference

12 December 2020

Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer

1 reference

12 December 2020

aFGF immunoreactivity in prostate cancer and its co-localization with bFGF and FGF8

1 reference

12 December 2020

Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma

1 reference

12 December 2020

Increased expression of fibroblast growth factor 6 in human prostatic intraepithelial neoplasia and prostate cancer

1 reference

12 December 2020

Gene amplifications associated with the development of hormone-resistant prostate cancer

1 reference

12 December 2020

Regulation of wound healing by growth factors and cytokines

1 reference

12 December 2020

Fibroblast growth factors are required for efficient tumor angiogenesis

1 reference

12 December 2020

Phase II trial of weekly alternating sequential BIBF 1120 and afatinib for advanced colorectal cancer

1 reference

12 December 2020

FGFR3 mutations in prostate cancer: association with low-grade tumors

1 reference

12 December 2020

14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myélome

1 reference

12 December 2020

Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro

1 reference

12 December 2020

A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy

1 reference

12 December 2020

10.1007/S11912-012-0225-0

Identifiers

DOI

1 reference

26 August 2017

1 reference